La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (July 2015)

17 slides from La Jolla Pharmaceutical's investor presentation, Jul 27, 2015

  1. Slide 1: LJPC-501 Market Opportunity

    July 2015 LJPC-501 Market Opportunity NASDAQ: LJPC

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: LJPC-501 Market Opportunity

    LJPC-501 Market Opportunity 3 • LJPC-501, La Jolla’s lead product candidate for catecholamine-resistant hypotension (CRH), is actively enrolling in a Phase 3 trial • Large market opportunity More than 125,000 patients suffer from CRH each year in US Attractive pricing potential • Positive feedback f

  4. Slide 4: LJPC-501: Overview

    LJPC-501: Overview 4 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • CRH is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current treatments • LJPC-501 has been shown

  5. Slide 5: Three Systems Work in Harmony to Regulate Blood Pressure

    Three Systems Work in Harmony to Regulate Blood Pressure 5 Current therapeutic options for the treatment of acute hypotension only leverage the adrenal system and vasopressin system The Body’s Three Systems that Regulate Blood Pressure

  6. Slide 6: High Doses of Catecholamines Increase Mortality

    High Doses of Catecholamines Increase Mortality 6 1Sviri et al, J. of Crit Care, 29;157-160, 2014 • Catecholamines (i.e., norepinephrine, epinephrine and dopamine) cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality1 0 10 20 30 40 50 60 70 80 90 Low Dose

  7. Slide 7: Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure

    Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure 7 Source: Chawla et al, Critical Care, 18:534, 2014 0 5 10 15 20 25 30 35 40 45 50 Pre2 Pre1 Hr0 Hr1 Hr2 Hr3 Hr4 Hr5 Hr6 Post1 Post2 N or ep in ep hr in e D os e (m cg /m in ) Placebo AT-II Arm Angio dose placebo gr

  8. Slide 8: LJPC-501: Phase 3 Trial in CRH

    LJPC-501: Phase 3 Trial in CRH SPA Agreement with FDA Reached, Trial Enrolling 8 • ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial initiated in March 2015 • Randomized, placebo-controlled, double-blind Phase 3 trial • Patient population: catecholamine-resistant, based on amount

  9. Slide 9: Market research overview

    9 • La Jolla recently engaged Decision Resources Group (DRG) and IMS Health (IMS) to conduct market research on the commercial opportunity of LJPC-501 • More than 125,000 patients suffer CRH, LJPC-501’s target market • Attractive pricing potential for LJPC-501 • Physicians, including P&T committee m

  10. Slide 10: Large Target Population

    10 LJPC-501: Market Opportunity Large Target Population Total Annual Hospitalized U.S. Population with Severe Hypotension Applicable Severe Hypotension: 65% Catecholamine-Treated Patients: 92% Catecholamine-Resistant* Patients: 38% LJPC-501 Target Market 555,479 361,684 332,189 126,232 *Catecholamin

  11. Slide 11: Attractive Pricing Potential

    LJPC-501: Market Opportunity Attractive Pricing Potential 11 Prices of Hospital-Based Drugs Reimbursed under DRGs Source: Wolters Kluwer PriceRx Pro, product package inserts, IMS Health inpatient/outpatient hospital charge master Catecholamine-Resistant* Catecholamine-Responsive Average total cost p

  12. Slide 12: Physicians Not Satisfied with Current Treatment Options

    12 LJPC-501: Market Opportunity Physicians Not Satisfied with Current Treatment Options New Mechanisms of Action Needed Lack of Effective Treatment Options • There is a need for treatments that treat the underlying causes of severe hypotension, especially for heart failure patients Complications wit

  13. Slide 13: Physicians See High Unmet Medical Need

    13 LJPC-501: Market Opportunity Physicians See High Unmet Medical Need 67% 20% 9% 6% 5% 0% 20% 40% 60% 80% 100% Tachycardia Hypoperfusion Necrosis Ischemia Arrhythmia % P at ie nt s Commonly Reported Side Effects with Catecholamines Increasing Need High Need = 10 Low Need = 1 60% of physicians repor

  14. Slide 14: LJPC-501 May Be a Game Changer

    14 • Physicians anticipate strong adoption of LJPC-501 in their practices Strong willingness to use in CRH based on evidence in primary endpoint alone Strong adoption predicted by P&T committee decision makers Earlier-stage use (e.g., first-line) for treatment of severe hypotension predicted by some

  15. Slide 15: Strong Interest Even among P&T Decision Makers

    LJPC-501: Market Opportunity Strong Interest Even among P&T Decision Makers 15 Robust (N=100) survey of physicians, 50% of which are P&T decision makers, shows strong interest based on evidence in primary endpoint alone Source: IMS Health survey, 2015 Endpoints Achieved Scenario 1 Scenario 2 Scenari

  16. Slide 16: Summary

    16 • LJPC-501, La Jolla’s lead product candidate for catecholamine-resistant hypotension (CRH), is actively enrolling in a Phase 3 trial • Large market opportunity More than 125,000 patients suffer from CRH each year in US Attractive pricing potential • Positive feedback from in-depth, physician mar

  17. Slide 17: Thank You

    Pharmaceutical Thank You

LA Jolla Pharmaceutical — Investor Presentation (July 2015) on 6ix